Obesity – Page 13

Pfizer Expands Collaboration with Flagship Pioneering, Adding Ampersand Biomedicines and Montai Therapeutics

11 months ago talkbio0Tagged Ampersand, Biomedicines, Drug Development, Flagship, Montai, Non-Small Cell Lung Carcinoma, Obesity, Pfizer, Pioneering, strategic partnership

Pfizer, Flagship Pioneering, Ampersand Biomedicines, Montai Therapeutics, strategic partnership, drug development, obesity, non-small cell lung cancer

GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial

11 months ago talkbio0Tagged Agonist, Amylin, GUBamy, long-acting, Obesity, phase 1 trial, Weight Loss

Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist

Metsera Secures $215M to Accelerate Obesity Drug Development

11 months ago talkbio0Tagged biotech, Glucagon-Like Peptide 1, Metabolic Diseases, Metsera, Obesity

Metsera, Obesity Drug, Funding, Biotech, GLP-1, Metabolic Disease

Metsera Secures $215 Million Series B Funding Following Promising Phase 1 Weight Loss Data

11 months ago talkbio0Tagged Glucagon-Like Peptide 1, Metsera, NuSH, Obesity, Peptides, Series B

Metsera, Series B funding, weight loss, obesity treatment, GLP-1 drugs, NuSH peptides

Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth

12 months ago talkbio0Tagged competition, Drug Industry, Eli, Eli Lilly, financial results, issues, Market, Nordisk, Obesity, Pricing, Q3 2024, Weight loss therapies

Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues

AstraZeneca Advances in Obesity Market with ECC5004 Deal and Promising Clinical Data

12 months ago talkbio0Tagged AstraZeneca, cardiometabolic diseases, GLP-1RA, Obesity, Weight Loss

AstraZeneca, obesity, ECC5004, GLP-1RA, cardiometabolic diseases, weight loss market

Viking Therapeutics’ Oral Weight Loss Drug VK2735 Shows Promising Phase 1 Results

12 months ago talkbio0Tagged GLP-1/GIP Dual Agonist, Obesity, oral weight loss drug, phase 1 trial, VK2735

VK2735, Viking Therapeutics, oral weight loss drug, GLP-1/GIP dual agonist, obesity treatment, Phase 1 trial results

Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes

12 months ago talkbio0Tagged Ascendis, Cardiovascular system, GLP-1 receptor, Metabolic Diseases, Nordisk, Obesity, once-monthly, Pharma, Technology, TransCon

Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.